Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice

Progress in Neuro-psychopharmacology & Biological Psychiatry
C DucottetCatherine Belzung

Abstract

Several recent studies on corticotropin-releasing factor (CRF) have suggested that this neuropeptide may play a role in depression. Consequently, CRF receptor antagonists have been proposed as potential new agents for the treatment of this condition. This study investigated the effects of a 4-week treatment with the well-known CRF(1) receptor antagonist, antalarmin, and the prototypical selective serotonin reuptake inhibitor (SSRI), fluoxetine, in the chronic mild stress (CMS) model in BALB/c mice. Animals were exposed to 9 weeks of CMS which rapidly (within 2 weeks) produced decrease of physical state (PS), body weight gain and blunted emotional response in the light/dark test. Chronic treatment with antalarmin (10 mg/kg ip) and fluoxetine (10 mg/kg ip) led to an improvement of CMS-induced modifications. These results suggest that CRF(1) receptor antagonists may represent potential antidepressants.

References

Jan 1, 1992·Neuroscience and Biobehavioral Reviews·P WillnerM Papp
Oct 25, 1984·The New England Journal of Medicine·F HolsboerO A Müller
Jan 1, 1984·Psychopharmacology·P Willner
Apr 1, 1996·Trends in Pharmacological Sciences·D T ChalmersE B De Souza
Mar 26, 1997·European Journal of Pharmacology·R S MansbachY L Chen
Nov 5, 1997·Pharmacology, Biochemistry, and Behavior·L K HeislerA Gerstein
Feb 13, 2001·The European Journal of Neuroscience·M E KeckR Landgraf
Oct 31, 2002·Human Psychopharmacology·Donna O'BrienCharles B Nemeroff

❮ Previous
Next ❯

Citations

Mar 26, 2013·Cell and Tissue Research·Olivia F O'Leary, John F Cryan
Nov 5, 2013·European Journal of Pharmacology·Brijesh G TaksandeNandkishor R Kotagale
May 19, 2005·Neuroscience and Biobehavioral Reviews·Martin E KeckMarianne B Müller
Jun 10, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alexandre SurgetEtienne Sibille
Sep 3, 2005·Nature Reviews. Drug Discovery·John F Cryan, Andrew Holmes
Aug 15, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jonathan G McEuenTracy L Bale
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Lee E SchechterSharon Rosenzweig-Lipson
Jul 24, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hong JiangDexiang Liu
Jul 19, 2014·Behavioural Brain Research·Hetty BoleijFrauke Ohl
Oct 1, 2007·Expert Opinion on Drug Discovery·Chad E Beyer, Zoë A Hughes
May 12, 2009·Expert Opinion on Investigational Drugs·Shrinivas K Kulkarni, Ashish Dhir
Sep 13, 2015·The International Journal of Neuropsychopharmacology·Miao-Jin JiHao Hong
Mar 24, 2011·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Elsa IsingriniVincent Camus
Oct 14, 2010·Psychoneuroendocrinology·Klaus V WagnerMathias V Schmidt
Jul 21, 2009·Behavioural Brain Research·Hiroyuki ArakawaRobert J Blanchard
Mar 3, 2009·European Journal of Pharmacology·Bernardo C DetanicoElaine Elisabetsky
Sep 16, 2008·Psychoneuroendocrinology·Yadira Ibarguen-VargasCatherine Belzung
Jul 2, 2008·Behavioural Brain Research·Hajnalka KompagneGyörgy Lévay
Jun 3, 2008·Journal of Ethnopharmacology·Angelo L PiatoElaine Elisabetsky
Feb 8, 2008·European Journal of Pharmacology·Alexandre Surget, Catherine Belzung
Mar 8, 2008·Pharmacology, Biochemistry, and Behavior·Xin LiangYan Dong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.